KRN5 manufacturers
- KRN5
-
- $197.00
-
2026-07-13
- CAS:1800465-47-7
- Purity: 99.85%
- Supply Ability: 10g
- KRN5
-
- $197.00
-
2026-07-13
- CAS:1800465-47-7
- Purity: 99.85%
- Supply Ability: 10g
|
| Product Name: | KRN5 | | Synonyms: | KRN5;8H-Benzo[g]-1,3-benzodioxolo[5,6-a]quinolizin-8-one, 13-[(2-fluorophenyl)methyl]-5,6-dihydro-9,10-dimethoxy-;KRN5,KRN-5;13-(2-Fluorobenzyl)-9,10-dimethoxy-5,6-dihydro-8H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-one;KRN5, 10 mM in DMSO | | CAS: | 1800465-47-7 | | MF: | C27H22FNO5 | | MW: | 459.47 | | EINECS: | | | Product Categories: | | | Mol File: | 1800465-47-7.mol |  |
| Boiling point | 682.0±55.0 °C(Predicted) | | density | 1.42±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 6 mg/mL (13.06 mM);Water : < 0.1 mg/mL (insoluble) | | form | Solid | | pka | -1.93±0.40(Predicted) | | color | Light yellow to yellow |
| Uses | KRN5, a derivative of KRN2, is an oral active Nuclear factor of activated T cells 5 (NFAT5) suppressor, with an IC50 of 750 nM. KRN5 has potential to treat NFAT5-mediated Chronic Arthritis[1]. | | in vivo | Oral feeding of KRN5 (15 mg/kg and 60 mg/kg) every other day for 3 weeks from day 21 dose-dependently mitigates arthritis severity[1].
The concentration of serum anti-type II collagen IgG also significantly decreases in the sera of KRN5-treated mice. TNF-α and IL-6 production by LPS-stimulated splenocytes are significantly lower in KRN5-treated CIA mice than in vehicle-treated mice[1]. | Animal Model: | 8-week-old DBA/1Jmice immunized with bovine type II collagen[1]. | | Dosage: | 15 mg/kg and 60 mg/kg. | | Administration: | Orally on alternate days (every other day) for 3 weeks. | | Result: | Dose-dependently mitigated arthritis severity. |
| | References | [1] Han EJ, et al. Suppression of NFAT5-mediated Inflammation and Chronic Arthritis by Novel κB-binding Inhibitors. EBioMedicine. 2017 Apr;18:261-273. DOI:10.1016/j.ebiom.2017.03.039 |
| | KRN5 Preparation Products And Raw materials |
|